secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2023-09-27T23:59:59+00:00
Accession:  0001104659-23-104272
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics enrolls 8th patient in SBMA trial, triggering 276,652 share issuance to AnnJi
--------------------------------------------------------------------------------

- Enrolled eighth patient in Phase 1b/2a trial of AJ201 for spinal and bulbar muscular atrophy (SBMA).
- Issued 276,652 shares of common stock to AnnJi as Second Tranche Shares under license agreement.
- Trial is 12-week, multicenter, randomized, double-blind, targeting ~24 patients; primary endpoint safety/tolerability.
- AJ201 activates Nrf1/Nrf2 and enhances androgen receptor degradation; previously paid $3M cash and 831,618 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465923104272/0001104659-23-104272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465923104272/tm2327078d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-104272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer